Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Surprise Boehringer Decision Turns Hanmi Investors’ Hopes To Despair

Executive Summary

Hanmi shares have gone on a wild roller coaster ride as bad news came after good. A day after it announced a huge licensing agreement with Genentech, the South Korean firm unveiled that Boehringer Ingelheim had decided to return rights to olmutinib, the EGFR inhibitor it licensed from Hanmi last July.


Related Content

SOLAR Eclipsed As Astellas Drops EGFR Inhibitor On Late-Stage Failure
Deal Watch: Sanofi Begins 2017 By Ending Vaccine JV, Completing Swap With Boehringer
Hanmi Toughens Controls As Employees Arrested For Insider Trading
Boehringer Targets Hearing Loss In First China Pharma R&D collaboration
Hanmi’s Case: One Failure Doesn’t Speak For All
Korea To Limit Olmutinib Usage, Monitor All Patients
Boehringer Ingelheim Bullish In Oncology Despite Olmutinib U-Turn
Boehringer’s Oncology Strategy: Build From Niche Lung Cancer Base
Boehringer Ingelheim Reveals Battle Plans For Olmutinib
ANALYSIS: Hanmi Deal Strengthens BI’s Hand But Competitors Ahead


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts